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1. Introduction 
Type I interferons (IFNs), namely IFN-/ß, were originally discovered due to its powerful 
antiviral activity [1, 2]. Type I IFNs were later shown to have pleiotropic biological activities, 
including modulation of innate and acquired immune responses, cell growth and apoptosis, 
in addition to their well-known ability to inhibit virus replication [3]. Type I IFN forms a 
vast multigenic family [4]. The human genome carries the intronless genes encoding 13 
functionally and structurally related IFN- subtypes and a single IFN-ß molecule [5]. In 
addition, it contains genes encoding for IFN- [6], IFN-/ [7], and IFN- [8]. In spite of this 
remarkable variability, all type I IFN subtypes appear to bind the same heterodimeric 
receptor [4].  
Type I IFNs have been used for the clinical treatment of several malignancies including 
renal cell carcinoma, melanoma, Kaposi’s sarcoma, hairy cell leukemia and chronic myeloid 
leukemia. For a long time, it was thought that the direct actions on tumor cells were the 
major mechanisms involved in the antitumor responses observed in type I IFN-treated 
patients [9]. Actually, type I IFNs are able to directly inhibit the proliferation of tumor cells 
in vitro and in vivo, and exert other direct effects on tumor cells including induction of 
apoptosis and enhancement of major histocompatibility complex (MHC) class I expression, 
which can enhance immune recognition [10]. In addition to the direct effects on tumor cells, 
type I IFNs exert multiple biological effects on host immune cells, especially T cells and 
dendritic cells, that can play a central role in the overall antitumor responses [11].  
Type III IFNs, also termed IFN-s, were discovered independently by 2 different research 
groups in 2003 [12, 13]. The type III IFN family consists of IFN-1, IFN-2 and IFN-3, also 
referred to as interleukin (IL)-29, IL-28A and IL-28B, respectively. On the basis of sequence 
and protein structure, type III IFNs are more similar to the IL-10 family of cytokines, but the 
deciding factor that led to the classification of IL-29, IL-28A and IL-28B as IFNs was their 
antiviral function and induction of IFN-stimulated genes (ISGs) [12, 13]. In humans, among 
these molecules, only IL-29 is glycosylated [12, 13]. In the mouse system, the IL-29 gene is a 
pseudogene. The IL-28A and IL-28B genes encode glycosylated protein [14]. 
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Type III IFN expression has been shown to depend on the same triggers (viral infection or 
Toll-like receptor (TLR) ligands) [12, 13, 15, 16, 17, 18, 19, 20] and signal transduction 
pathway as those inducing type I IFN expression. Type I IFNs and type III IFNs bind 
distinct heterodimeric receptors [12, 13]. The type I IFN receptor is made of the ubiquitously 
expressed IFN-R and IFN-Rß subunits [21]. The type III IFN receptor is comprised of the 
IL-10Rß subunit which is widely expressed and shared by other IL-10-related cytokines, and 
of the IL-28R subunit, which is specific to type III IFN and responsible for signal 
transduction [12, 13, 21]. While the receptor subunits of type III IFNs display no detectable 
homology to those of type I IFNs, they elicit strikingly similar intracellular responses, 
mostly through the activation of several latent transcriptional factors of the signal 
transducer and activator of transcription (STAT) family including STAT1, STAT2, STAT3, 
STAT4 and STAT5 [12, 22, 23]. In particular, type III IFN receptor engagement leads to the 
phosphorylation of STAT1 and STAT2 and the formation of the interferon-stimulated gene 
factor 3 (ISGF3) transcription complex, which is composed of STAT1, STAT2 and IFN 
regulatory factor (IRF) 9/p48 [12], and to the induction of myxovirus resistance A (MxA) 
and oligoadenylate synthetase (OAS)1, which mediate the antiviral effects of type I IFN [12, 
24]. Initially, type I IFNs and type III IFNs were also considered to lead to activation of the 
mitogen-activated protein (MAP) kinases c-Jun N-terminal kinase (JNK) and p38, but not 
extracellular signal-regulated kinase (ERK) [24]. Accordingly, type III IFNs have been shown 
to elicit biological activities including antiviral, antiproliferative and immunomodulatory 
properties, similar to those of type I IFNs. Therefore, despite the structural difference and 
the utilization of a distinct receptor system, type III IFN seems to be functionally related to 
type I IFN.  
In the first half of this chapter, we will summarize the current knowledge on the novel IFN 
family member type III IFN and, in the latter half, we will review studies from several 
laboratories, including our group, displaying direct and indirect antitumor activities of type 
III IFNs with the usage of various histological types of human tumor cell lines and 
xenogeneic models of human esophageal carcinoma and non-small cell lung cancer 
(NSCLC), and genetically modified tumor cells in murine tumor models. 
2. Type III IFN-encoding genes and regulation of production 
In 2003, two research groups independently reported the identification of a small family of 
interferon like cytokines through computational analysis of the human genome sequence 
database [12, 13]. This novel family of interferon consists of three family members, which 
were referred to alternatively as IFN-1, IFN-2 and IFN-3, or IL-29, IL-28A, and IL-28B, 
respectively. The genes encoding human IL-28A, IL-28B and IL-29 are located on the same 
genomic contig, which is from chromosomal region 19q13.13 [12, 13]. This chromosomal 
location differs from the type I and type II interferon families clustered on chromosome 9 
and chromosome 12, respectively. The genes encoding type III IFNs are composed of 
multiple exons, 5 for IL-29, and 6 for IL-28A and IL-28B, resembling the structural 
organization of genes encoding IL-10-related cytokines [12, 13]. This is in clear contrast to 
type I IFNs, which are encoded within a single exon. At amino acid level, IL-28A has an 81-
96% identity to IL-28B and IL-29, 11-13% identity to IL-10 and 15-19% identity to IFN- and 
IL-22 [12, 13]. 
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Mouse type III interferon-encoding genes were mapped to chromosome 7A3. This region 
has a similar organization as the human type III interferon locus [14]. Two genes colinear 
with the human IL-28A and IL-28B genes are intact and are predicted to encode functional 
proteins, which are designated mouse IL-28A and IL-28B in accordance with the 
corresponding human genes [14]. Mouse IL-28A and IL-28B have higher sequence identity 
to human IL-28A and IL-28B than to IL-29 [14]. In contrast to the IL-28A and IL-28B genes, 
the mouse IL-29 gene has lost the entire exon 2 and acquired the stop codon within exon 1, 
resulting in a pseudogene in all murine strains studied [14]. Both mouse IL-28A and IL-28B 
possess a site for N-linked glycosylation (Asn105-Met-Thr in IL-28A and Asn107-Asp-Ser in 
IL-28B) [14].  
Like type I IFNs, type III IFN mRNAs expression was detected at low levels in human blood, 
brain, lung, ovary, pancreas, pituitary, placenta, prostate, and testis by RT-PCR analysis [25]. 
Furthermore, there have been many reports that infection of encephalomyocarditis virus 
(EMCV) [13], Sindbis virus [25], Dengue virus [12], vesicular stomatitis virus (VSV) [10], 
mengo virus [23], cytomegalo virus (CMV) [24], and Sendai virus [27, 28, 29] leads to 
transcriptional activation of IL-28A, IL-28B, and IL-29 variously in human peripheral 
mononuclear cells (PBMC), monocyte-derived dendritic cells (MD-DCs), bronchial epithelial 
cells and a number of human cell lines. Respiratory syncytial virus induces expression of 
type III IFNs in monocyte-derived macrophages [30]. Type III IFN mRNAs are co-expressed 
with IFN- and IFN-ß in virally infected cells [10, 11]. Sendai virus infection readily 
activates the expression of IFN-, IFN-ß, and IFN- genes, whereas influenza A virus (IAV)-
induced activation of these genes is mainly dependent on pretreatment of A549 lung 
alveolar cell carcinoma with IFN- or tumor necrosis factor (TNF)- [31]. Although virtually 
any cell type following viral infection can express type III IFNs, PBMC, MD-DCs and 
plasmacytoid DCs appear to be the major cellular sources [10, 11, 32]. The antigen 
presenting cells (APCs) such as DCs and macrophages have been shown to produce and 
secrete type III IFNs following stimulation with TLR agonists [25, 33]. MD-DCs express low 
levels of type III IFNs when stimulated with TLR agonists such as lipopolysaccharide (LPS) 
or polyinosinic:polycytidylic acid [poly(I:C)]. In addition, type III IFNs also have a positive 
regulatory effect on the expression of type III IFNs. Siren et al. [27] demonstrated this clearly, 
whereas pretreatment with type III IFNs was shown to enhance the production of type III 
IFNs by macrophages stimulated with TLR3 and TLR4 agonists. TLR3 ligand poly(I:C) up-
regulated IFN-ß, IFN-, and TLR3 expression in HUVECs but not in A549 cells. Similarly, 
IFN- pretreatment also strongly enhanced poly(I:C)-induced activation of IFN- and IFN 
genes in HUVECs [33]. Although type III IFNs differ genetically and structurally from type I 
IFNs and use their own specific receptor, the expression of type III IFNs and type I IFNs is 
regulated in a similar fashion in virus-infected cells exhibiting both early and late phases of 
interferon induction [15]. However, type III interferon genes are under a more complex 
regulation than type I interferon genes, since type III interferon genes have a higher number 
of regulatory elements on their promoters [15]. Type III interferon gene promoters have 
several putative IFN-stimulated response elements (ISRE) and NF-B binding sites [30]. The 
promoter sequences of IL-28A and IL-28B genes are almost identical, whereas the promoter 
of IL-29 is somewhat different from the IL-28A/B promoters [25]. Namely, NF-B and 
multiple IRF family members induce the expression of IL-29 gene [25]. In contrast to IL-29, 
the IL-28A/B genes are predominantly regulated by an IFN regulatory factor (IRF) family 
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member IRF7 [25]. Therefore, the IL-29 gene is mainly regulated by virus-activated IRF3 and 
IRF7, resembling that of the IFN-ß gene, whereas IL-28A/B gene expression is mainly 
controlled by IRF7, resembling those of IFN- genes [25]. Viral infection serves to activate 
IRF3, which is expressed broadly and constitutively at high levels in cells, via specific serine 
phosphorylation events, leading to the synthesis and release of IFNs, predominantly IL-29 
and IFN-ß. In paracrine fashion, these newly released IFNs are free to act on neighboring 
cells. The binding of IFNs to the respective specific receptor induces expression of another 
transcriptional activator, IRF7, in a STAT1-dependent manner. When cells expressing other 
IRF7 are in turn infected with viruses, IRF7 is phosphorylated, and the cells respond by 
expressing other type III IFN and type I IFN genes, such as IL-29, IL-28A/B, IFN- and  
INF-ß.  
3. Type III IFN receptor subunit IL-28R 
Type III IFNs act through a cell surface receptor which is composed of the newly identified 
IL-28R and IL-10Rß with both chains apparently required for full binding affinity [12, 13]. At 
the time of its discovery, IL-10Rß has been already known as the second chain of the IL-10 
[34], IL-22 [35, 36], or IL-26 receptor [37], formerly known as the class II cytokine receptor 
(CRF2)-9. IL-28R belongs to members of the class II cytokine receptor family, which are 
tripartite single-pass transmembrane proteins defined by structural similarities in the 
extracellular domain including the ligand binding residues [37, 38]. In accordance with the 
CRF2 characteristics, both transmembrane chains have an extracellular moiety containing 
two tandem fibronectin III domains, a structural motif in the immunoglobulin fold 
superfamily, with several amino acid (aa) positions conserved within this receptor family 
[38, 39]. Like IL-10, IL-22 and IL-26, the binding of type III IFN to IL-28R induces a 
conformational change that enables IL-10Rß to interact with the newly formed ligand-
receptor complex [40]. 
The human IL-28R-encoding gene is located on chromosomoe 1p36.11, near the IL22RA1 
locus, while the IL-10R-encoding gene is located on 21q22.11, near the IFNAR1, IFNAR2, and 
IFNGR2 loci [12, 13, 41]. The first exon of the human IL-28R-encoding gene contains 5-UTR 
and the signal peptide [12, 13]. The transmembrane moieties are predicted to be encoded by 
sequences derived from exon 6 of the corresponding genes [12, 13]. The longer intracellular 
moiety of IL-28R (predicted 271 aa versus 79 aa in the IL-10Rß) contains three tyrosine 
residues, which are potential targets for phosphorylation [12, 13]. Dumoutier et al. indicated 
two tyrosines Tyr343 and Tyr517 of human IL-28R can independently mediate STAT2 
activation by type III IFNs [23]. This work also showed that when both tyrosines343 and 517 
were mutated to phenylalanine, antiviral and antiproliferative activities of type III IFNs 
were completely abolished [23]. The extracellular domains of IL-28R and IL-10Rß contain 
four putative N-linked glycosylation sites [12, 13]. 
The murine genes encoding IL-28R and IL-10Rß are located on chromosome 4D3 and 16C4, 
respectively [14]. The mouse IL-28R chain is ~67% similar to its human counterpart [14]. 
Although the mouse and human IL-28R sequences are similar, only two of three tyrosine 
residues of the human receptor intracellular domain are conserved in the mouse orthologue 
[14]. The mouse receptor contains three additional tyrosine residues [14]. The Try341-based 
motif of mouse IL-28R (YLERP) shows similarities with that surrounding Tyr343 of human 
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IL-28R (YLERP). In addition, the COOH-terminal amino acid sequence of mouse IL-28R 
containing Tyr533 (YLVRstop) is similar to the COOH-terminal amino acid sequence of 
human IL-28R containing Tyr517 (YMARstop). Therefore, both the mouse and human IL-28R 
chains contain similar docking sites for STAT2 recruitment and activation. Human IL-28R 
has a stretch of negatively charged residues close to the end of the intracellular domain. This 
region in the mouse IL-28R is significantly altered by a short insertion and substitution of 
several amino acid residues, resulting in a longer and more negatively charged region in the 
mouse receptor [14]. 
Several research groups including our own have examined the expression of IL-28 receptor 
complex components. The IL-10Rß chain is ubiquitously expressed, which can be explained 
by its function as part of several cytokine receptors. The one notable exception is the brain, 
where the IL-10Rß chain seems to be expressed at very low levels [42]. Therefore, the 
expression of the IL-28R chain should determine whether a cell is responsible to the type III 
IFNs or not [12, 13]. The near relation of type III IFNs to type I IFNs and IL-10 initially 
suggested extensive effects of type III IFNs on various cell populations. Actually, Sheppard 
et al. observed at first that, using northern blot analysis, various organs variably expressed 
the major IL-28R transcript and therefore contain putative target cells in humans [13]. These 
organs include the adrenal gland and kidney, and those from the digestive (stomach, small 
intestine, colon and liver), respiratory (lung) and immune (spleen and thymus) systems, 
with the highest expression found in the pancreas, thyroid, skeletal muscle, heart, prostate, 
and testis [13]. Interestingly, most IL-28R mRNA-expressing tissues form outer body 
barriers and contain epithelial cells [43]. These quantitative results are in line with the data 
published by Kotenko et al. [9]. A pattern similar to that obtained in tissues using northern 
blot analysis was found in corresponding hematopoietic (HL-60 promyelocytic leukemia, K-
562 erythroleukemia, MOLT-4 T-cell leukemia and Raji B-cell leukemia) and non-
hematopoietic (HeLa S3 cervical adenocarcinoma, Caco-2, SW480, HCT116, SW480 and 
DLD-1 colorectal adenocarcinoma, A549 lung alveolar cell carcinoma, LK-1 lung 
adenocarcinoma and G-361 melanoma) cell lines [12, 44, 45].  
At present, it has been thought that the surface expression of IL-28R is more restricted 
relative to the type I IFN receptor although detailed information regarding with the 
expression level and cell distribution of the type III IFN specific receptor IL-28R is relatively 
limited. Therefore, whereas type I IFN signaling is observed for a broad spectrum of cell 
types, type III IFN signaling is generally weaker and more restrictive, which is correlated 
with a low expression of the IL-28R subunit of the type III IFN receptor. Actually, at the 
cellular level, B cell lymphoma Raji and hepatoma HepG2 cells respond well to type III IFNs. 
On the contrary, in HT1080 fibrosarcoma, Sw13 adrenal carcinoma cells and MCF-7 breast 
cancer cells, all of which respond to type I IFNs, no significant response to type III IFNs was 
observed [26]. Furthermore, in humans, primary bronchial epithelial cells and primary 
gastric epithelial cells are responsive to type III IFNs, whereas primary fibroblasts and 
umbilical vein endothelial cells do not express IL-28R and therefore are not responsive to 
type III IFNs (14 and our unpublished observation).  
In mouse, IL-28R mRNA expression has been found in keratinocyte and lung fibroblast [14, 
46]. In immune systems, our studies using RT-PCR did not detect any expression of IL-28R 
mRNA in primary spleen cells from C57BL/6 mice [43, 46]. Moreover, we could not detect 
any IL-28R expression in resting primary immune cells such as B cells and T cells [46]. Lasfar 
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et al. also observed that primary lymphocytes and macrophages, the major players in 
specific antitumor immunity, are found to be unresponsive to type III IFN [14]. In 
accordance with the results obtained with primary immune cell subpopulations, 
corresponding cell lines (EL4 and P815) expressed IL-10Rß but not IL-28R [44]. On the 
contrary, Siebler et al. reported the opposite finding that the IL-28R mRNA is expressed in 
primary murine CD4 T cells [48]. In the case of NK cells, Murakami’s group demonstrated 
the mRNA expression of IL-28R [47]. Further analyses are needed to determine the precise 
expression profile among immune cells. In general, tissues which are mainly composed of 
epithelia such as intestine, skin, or lung are the most responsive to type III IFNs. These data 
indicate that a key difference between the type I IFN and type III IFN systems could be the 
cell specificity of their respective receptor expression. 
4. Signal transduction of type III IFNs 
Signaling induced by a cytokine binding to type II cytokine receptor, whose extracellular 
parts commonly consist of tandem fibronectin type III domains and the cytoplasmic domain 
is associated with a tyrosine kinase of the Janus kinase (Jak) family, is known to occur 
primarily via the Jak/STAT pathway. Both IL-28R and IL-10Rß subunits are necessary to 
form a functional type III IFN receptor. The formation of the IL-28R-IL-10Rß ternary 
complex initiates signaling events by activating the transduction elements bound to the 
intracytoplasmic part of the two chains composed of functional type III IFN receptor. Type 
III IFNs induce the activation of a Jak/STAT signaling pathway leading to tyrosine 
phosphorylation of STAT1, STAT2, STAT3, STAT4 and STAT5 [12, 13, 22, 23, 49]. In 
structure, IL-28R is most closely related at the sequence level with the soluble class II 
cytokine receptor IL-22R2, whereas a second type III IFN receptor chain IL-10Rß is 
commonly utilized by IL-10, IL-22 and IL-26 [38]. IL-10, IL-22 and IL-26 can stimulate STAT3 
phosphorylation, and IL-22 and IL-26 have been shown to phosphorylate STAT1. On the 
other hand, only the type III IFN family induces tyrosine phosphorylation of STAT2. The 
characteristics to be able to phosphorylate STAT1, STAT2 and STAT3 are common to the 
type III IFN family and the type I IFNs. Thus, STAT2 activation has been, at present, 
restricted to type I IFNs and type III IFNs. From studies of IL-10 and IL-22 signal 
transduction, it is known that its short (82 amino acids) intracytoplasmic part binds tyrosine 
kinase Tyk2 but does not provide STAT recruitment sites [50]. Jak1 was shown to be critical 
in mediating IFN-induced STAT phosphorylation [22]. Thus, it is likely that, as for the type I 
IFN receptor system, Jak1 and Tyk2 are the two tyrosine kinases associated with the type III 
IFN receptor subunit and mediating STAT activation. STAT2 is specifically recruited in the 
ISGF3 transcription factor that translocates to the nucleus and drives the expression of the 
gene family carrying an ISRE sequence in their promoter. ISGF3 is formed by dimerization 
of STAT1 and STAT2 via SH2 phosphotyrosine interactions and association of the 
heterodimer with IRF9. Type III IFNs induce the formation of both ISGF3 and STAT1 
homodimers, which are able to recognize ISRE and GAS sequences [12, 14, 23]. Among the 
IFN-induced genes, suppressor of cytokine signaling (SOCS)1 and SOCS3 are involved in 
the negative regulation of type III IFN signaling [51, 52]. Overexpression of SOCS1 in 
hepatic cell lines inhibits type III IFN signaling as well [51]. Additionally, type I IFNs can 
activate a variety of signaling molecules and cascades, which may operate in concert with or 
independently of STATs. Similarly, type III IFNs were shown to activate ERK 1/2 and Akt 
in an intestinal epithelial cell line [44].  
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Fig. 1. Signaling pathways of type III IFNs, which activate similar intracellular signaling 
components and genes to type I IFNs. 
5. Direct antitumor activity of type III IFNs 
One of the most important properties of type I IFNs is their potential in cancer treatment. 
Type I IFNs represent the cytokines exhibiting the longest record of use in clinical oncology 
[53]. Even though today some new anticancer drugs somehow replaced type I IFNs in the 
treatment of certain hematological malignancies such as hairy cell leukemia and chronic 
myeloid leukemia, type I IFN therapy continues to be widely used in the adjuvant treatment 
of certain malignancies such as melanoma and renal cell carcinoma [54, 55]. As mentioned 
earlier, signaling components are shared between type I IFNs and type III IFNs. Therefore, 
based on the similar functional profiles with type I IFNs, it would be anticipated that type III 
IFNs would have redundant antitumor properties.  
Several research groups have investigated the antitumor potential of type III IFNs. Until 
now, growth-inhibitory action of type III IFNs has been documented in certain histological 
types of human tumors such as neuroendocrine tumors [52], esophageal carcinoma [56], 
colorectal/intestinal carcinoma [51], hepatocellular carcinoma [16, 57, 58], lung 
adenocarcinomas [45], Burkitt’s lymphoma [26], and melanoma [59]. These are summarized 
in Table 1. 
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Table 1. Representative antitumor activity of type III IFNs 
In vitro studies using multiple human cell lines including B cell lymphoma, hepatoma, 
neuroendocrine and colorectal tumor cell lines provide evidence that, in these lines, type III 
IFNs can induce 2’-5’ oligoadenylate synthetase (2’,5’-OAS), which is involved in type I IFN-
induced antiproliferative effects [12, 23, 44]. A study of ours also displayed that type III IFNs 
significantly suppressed in vitro growth of human NSCLC lines and markedly up-regulated 
mRNA expression of 2’,5’-OAS in these lines [60]. Therefore, 2’,5’-OAS could, at least in part, 
contribute to the antiproliferative effect of type III IFNs. On the other hand, Brand et al. 
reported that the mRNA expression levels of protein kinase R (PKR) in intestinal epithelial 
cell lines remained unchanged after type III IFN treatment [44]. PKR mediates the 
antiproliferative function via inhibition of protein synthesis, and is also involved in the 
growth-inhibitory actions of type I IFNs. Additionally, we observed the same findings in 
human respiratory epithelial cell lines [60]. In contrast, in both hepatoma and B cell lines, 
type IIII IFNs mediated PKR gene induction [57]. Collectively, PKR could be involved in 
type III IFN-induced antiproliferative effect in a limited range of cell types.  
Type I IFNs can exert a more direct negative regulatory effect on the cell cycle by specifically 
up-regulating expression of a number of cyclin-dependent kinase inhibitors (CKIs). Type I 
IFNs specifically enhance the expression level of p21Waf1/Cip1, which plays a crucial 
regulatory role in the progression from the G1 to S phase [61]. Type I IFNs also increase 
expression of another CKI p15Ink4b that can complex specifically with Cdk4 [62]. A third 
protein p27Kip1 preferentially binds to cyclinE/Cdk2 complexes, and dissociation of the 
retinoblastoma gene product (pRb) and the related pocket proteins (p107 and p130) is 
concomitantly suppressed [63]. Rb and the related pocket proteins, in their non-
phosphorylated forms, interact strongly with the E2F family of transcription factors, thus 
inhibiting their activity [64]. Phosphorylation of Rb (and p107 or p130) normally releases 
E2F transcription factors, and permits transition from the G1 to S phase. 
Our recent study demonstrated that, in a panel of human esophageal carcinoma cell lines, 
the T.Tn cell line was susceptible to the apoptotic effects of type III IFNs, whereas type I 
IFNs elicited neither an antiproliferative nor a pro-apoptotic response [56]. p21Waf1/Cip1 was 
initially expressed at high levels in T.Tn cells, and a large fraction of these cells were in the 
G0/G1 phase as a possible consequence of high levels of p21Waf1/Cip1 expression. In addition, 
our studies using multiple human NSCLC lines displayed elevated p21Waf1/Cip1 mRNA 
expression and, to a lesser extent, p27Kip1, but not p15Ink4b, expression with type III IFN 
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treatment, and that knockdown of p21Waf1/Cip1 with a p21Waf1/Cip1-specific double-stranded 
small inhibitory RNA (p21-siRNA) oligonucleotide largely attenuated the observed 
antiproliferative effect, suggesting the major role of p21Waf1/Cip1 in the growth-inhibitory 
function of type III IFNs [60]. Analysis of cell cycle distribution displayed that treatment of 
NSCLC lines with type III IFNs resulted in an accumulation of cell numbers in the G1 phase 
in a dose-dependent manner. This increase of the G1 population was accompanied by the 
reduction of S and G2 populations. Taken collectively, our results demonstrated that type III 
IFNs could induce cell cycle arrest at the G1 phase. These findings are in line with the result 
published earlier by Sato et al. [47].  
Another important mechanism for type III IFNs to exert an antiproliferative effect was 
reported by Zitzmann’s research group [52]. They demonstrated that treatment with type III 
IFN significantly suppressed the growth of human neuroendocrine BON1 tumor cells, but 
did not result in a significant accumulation in G1 phase [52]. Moreover, the same research 
group indicated that incubation with type III IFN significantly increased the amount of 
cleaved caspase-3- and poly(ADP-ribose)polymerase (PARP)-products in BON1 tumor cells 
[52]. In this case, treatment with type III IFN resulted in induction of apoptosis rather than 
in the interference of cell cycle progression. Moreover, Sato et al. reported that type III IFNs 
up-regulated surface expression of FAS, dephosphorylated Rb and activated both caspase-3 
and caspase-7 in B16 melanoma cells, suggesting the promotion of apoptosis [47]. Our 
studies displayed that type III IFNs induced apoptosis in NSCLC cells by measuring DNA 
fragmentation and surface Annexin V expression when NSCLC cells were treated for 
relatively long periods [60]. In addition, Brand et al. indicated that type III IFNs did not 
influence FAS ligand-induced apoptosis but decreased cell proliferation in human intestinal 
epithelial cells [24].  
Maher et al. demonstrated that type III IFN treatment induced a prolonged but overall 
stronger activation of STAT1 and STAT2 in the immortalized keratinocyte line HaCaT 
compared with IFN- treatment [65]. Another distinctive difference was the induction of 
ISGs by IFN-, which peaked early and declined thereafter, whereas IFN--induced ISGs 
levels peaked later but were sustained longer. A substantial growth inhibitory response, 
activation of caspase-3 and caspase-7, and ultimately apoptosis ensued. Although IFN- 
induced a modest antiproliferative effect, it did not promote apoptosis, suggesting that the 
prolonged STAT activity and subsequent induction and sustained expression of ISGs are 
what may have favored the activation of programmed cell death. Pretreatment of HaCaT 
cells with pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone 
(Z-VAD-fmk) inhibited apoptosis, indicating a requirement for caspases in the promotion of 
type III IFN-induced cell death. The combination of IFN- and type III IFN had additive an 
antiproliferative effect, suggesting that the distinct receptor complexes did not compete for 
available JAKs and STATs or, alternatively, the type I IFN and type III IFN signaled partially 
through alternative pathways. Li et al. [66] have also demonstrated that type III IFN 
signaling leads to the activation of apoptosis. In their model, a human HT29 colorectal 
adenocarcinoma cell line with ectopic expression of a chimeric IL-10Rß/IL-28R that binds 
IL-10, but signals through the intracellular domain of IL-28R, was shown to undergo 
apoptosis when treated with IL-10. The early response was antiproliferative but later 
switched to one of apoptosis as a drastic increase in the proportion of sub-G0 cells was 
observed. Caspase-3, caspase-8 and caspase-9 were cleaved and activated, and pretreatment 
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with Z-VAD-fmk abrogated caspase-3 and caspase-9 activities, but did not block the death-
inducing effect of IL-10, indicating the presence of an additional cell death pathways. 
Surprisingly, Z-VAD-fmk increased the cleavage of pro-caspase-9 into caspase-9. The 
strength of STAT1 activation by IL-10 through the chimeric receptor was more robust than 
treatment with type III IFN that signaled through the endogenous IL-28R complex. Of note, 
HT29 cells express low levels of IL-28R and can respond to type III IFN by up-regulating 
MHC class I expression, but they are not growth inhibited by type III IFN. This raises an 
important point as it suggests that a sufficient number of cell surface IL-28R must be 
expressed and engaged for type III IFN to induce an antiproliferative effect. These studies 
are in agreement with our findings and strongly suggest that the strength of type III IFN 
signaling through STAT activation may be the determining factor that favors an apoptotic 
response. 
Antiproliferative and pro-apoptotic effects of type III IFN can be augmented when used in 
combination with chemotherapy drugs. Lesinski et al. reported that co-treatment of F0-
melanoma cells with proteasome inhibitor Bortezomib and type III IFN synergistically 
increased cell death, similar to the combination of IFN- and Bortezomib [67]. We also 
observed that the combination of 5-fluorouracil (5-FU) or cisplatin (CDDP) with type III IFN 
drastically inhibited cell growth of the esophageal carcinoma cell lines [56]. When 
esophageal carcinoma cell lines TE-11, YES-5 and T.Tn cells, which were sensitive to 
antiproliferative effect of type III IFN IL-29, were cultured with various doses of 5-FU or 
CDDP, IL-29 significantly enhanced the cytotoxicity of 5-FU or CDDP. This combinatory 
effect was additive irrespective of the agents. In contrast, IL-29 scarcely influenced the 
cytotoxicity of 5-FU or CDDP in normal and Het-1A cells, whereas IFN- enhanced the 
sensitivity of normal and Het-1A cells to 5-FU or CDDP. 
Our recent study demonstrated that antiproliferative effects of type III IFNs could be also 
enhanced when combined with type I IFN IFN- [60]. Treatment with interferon 
combination of type III IFN and type I IFN increased p21Waf1/Cip1 expression, and induced 
apoptotic cell death more efficiently, and consequently exerted an additive growth-
inhibitory effect on NSCLC lines in vitro. In addition, interferon combination therapy of IL-
29 and IFN- inhibited in vivo growth of xenogeneic NSCLC OBA-LK1 tumors more 
effectively than individual regent alone [60].  
One of the important mechanisms of antitumor activities of type I IFNs is inhibition of 
tumor-induced angiogenesis [68]. Type I IFNs can inhibit a number of steps in the 
angiogenic processes, including proliferation and migration of vascular endothelial cells [69, 
70, 71, 72]. Type I IFNs can also affect the expression of several angiogenic factors, including 
vascular endothelial growth factor (VEGF) [73], bFGF [74], IL-8 [75], and collagenase type IV 
in tumor cells and surrounding stroma cells [76]. Indeed, systemic therapy with the use of 
recombinant type I IFNs produces antiangiogenic effects in vascular tumors including 
hemangioma [77], Kaposi’s sarcoma [78], melanoma [79], and bladder carcinoma [80].  
In contrast to type I IFNs, there have been no reports demonstrating type III IFNs possess 
antiangiogenic activities. One of the key differences reported between the type I IFN and 
type III IFN systems is in the expression of their respective receptor subunits. For example, 
vascular endothelial cells express IFN-R, IFN-Rß and IL-10Rß, but not IL-28R, on the cell 
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surface [14]. Therefore, vascular endothelial cells appear to be, in general, unresponsive to 
type III IFNs. In addition, type III IFN treatment up-regulated, not suppressed, the secretion 
of proangiogenic cytokine IL-8 from human colon cancer cells [24]. Additionally, exposure 
of human macrophages to type III IFN IL-29 significantly induces IL-8 production [81]. In 
contrast, Pekarek et al. reported that, using human peripheral blood mononuclear cells, type 
III IFN member IL-29 elevated mRNA expression levels of three chemokines, monokine 
induced IFN- (MIG), IFN- inducible protein 10 (IP-10) and IFN- inducible T cell  
chemoattractant (I-TAC) in the absence of other stimuli [82]. These factors are members of 
the ELR- subfamily of CXC chemokines and display potent inhibitory effects on 
angiogenesis. In our xenogeneic NSCLC tumor models, daily intratumoral administration of 
IL-29 significantly suppressed in vivo tumor growth, but did not affect the tumor 
microvascular density [78]. Taken collectively, it is still now unknown whether type III IFNs 
possess antiangiogenic properties like type I IFNs. Further detailed analyses are needed to 
elucidate the biological role of type III IFN in angiogenesis.  
6. Induction of antitumor immunity by type III IFNs 
Several laboratories including ours carried out an ensemble of studies where the mouse type 
III IFN IL-28A gene was transduced into different types of mouse tumor cells and in vivo 
behavior of genetically modified cells constitutively secreting IL-28A was evaluated after 
injection into immunocompetent syngeneic mice [14, 46, 47]. In these experiments, a gene 
therapy approach was introduced to investigate whether type III IFNs may possess 
antitumor actions instead of systemic therapy because cytokine gene therapy has many 
advantages in comparison with systemic administration of cytokine. Systemic delivery of 
cytokines at pharmacologic doses results in a high concentration of cytokines in the 
circulation and often in suboptimal levels in tissues at the site of tumors. In contrast, 
cytokine gene transfer allows the localized expression of the cytokine at the targeted sites, 
avoiding deleterious side effects and resembling the paracrine mode of action of cytokines, 
which are produced in high amounts at the site of tumors and act on the immune system by 
providing transient signals between cells to generate effector responses. 
Ahmed et al. first investigated whether the constitutive expression of IL-28A at the tumor 
site may affect the tumorigenicity of B16 melanoma cells, which are responsive to type III 
IFNs and classified as a low immunogenicity [14]. This study provided initial evidence that 
the tumorigenicity of B16 cells producing IL-28A in immunocompetent mice is highly 
impaired or completely abolished, and that the inhibition of tumor establishment is 
dependent on the amount of IL-28A released by the genetically modified tumor cells [14]. 
Whereas 50% of mice injected with B16 clone producing 100 to 150 ng of IL-28A for 24 hours 
per 106 cells developed tumors, 100% of animals injected with B16 clone releasing 1 to 5 ng 
of IL-28A developed tumors. When B16 clone, which produced IL-28A but was resistant to 
the antiproliferative effect of IL-28A, was used to examine whether the antitumor effect of 
IL-28A was due to direct action on B16 cells or mediated by a host response, type III IFN-
unresponsive B16 clone expressing IL-28A displayed reduced tumorigenicity and repressed 
the growth of parental B16 cells in vivo to a level comparable to IL-28A-responsive B16 cells, 
providing evidence that host-defense mechanisms play a major role in mediating type III 
IFN-induced antitumor activity in vivo [14]. In this tumor model, about 10% mice, which 
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rejected B16 melanoma cells producing IL-28A, survived the subsequent parental B16 tumor 
challenge, suggesting the failure of development of a strong long-lasting immune memory 
[14]. Taken together with the findings that tumor-infiltrating immune cells were not 
observed in tumor tissues from B16 cells secreting IL-28A and mouse primary lymphocytes 
and macrophages are unresponsive to type III IFNs, it was proposed as one of the possible 
mechanisms that IL-28A produced by genetically modified B16 cells could first act on 
neighboring keratinocytes and other tumor stromal cells, and could inhibit their tumor-
supportive function, leading to the reduced tumorigenicity in the B16 melanoma tumor 
model [14].  
The antitumor therapeutic potential of type III IFN gene transfer into experimental tumors 
was further evaluated in animal models by another research group using various 
approaches, comprising both the use of genetically modified cells and in vivo delivery of 
type III IFN gene via injection of naked plasmid DNA. To examine the antitumor potency of 
type III IFNs in vivo, Sato et al. transfected B16/F0 mouse melanoma cells with IL-28A cDNA, 
which resulted in in vitro growth inhibition and increased caspase-3 and caspase-7 activity 
[47]. Transduction of IL-28A increased p21Waf1/Cip1 levels and decreased phosphorylation of 
Rb (Ser780), suggesting a mechanism for the observed cell arrest. In addition, B16/F0 cells 
producing IL-28A did not form pulmonary metastasis when injected into C57BL/6 mice. 
Histological examination of the lungs revealed cellular infiltrates and NK cells were 
demonstrated to be responsible for the major part of antitumor effect of type III IFN [47]. 
Moreover, the biological effects of ectopic IL-28A, secreted by the injected tumor cells, on 
the host’s immune response have been thoroughly investigated. Targeting of Colon 26 liver 
metastatic lesions by hydrodynamic gene delivery of plasmid DNA encoding mouse IL-28A 
led to marked reduction of liver metastatic foci along with survival advantages [47]. By 
studying the in vivo turnover of different lymphocyte subsets in mice injected with IL-28 
plasmid DNA, the number of NK cells and NKT cells in the liver markedly increased [47]. In 
contrast, B16 lung metastases were not successfully treated by hydrodynamic injection of IL-
28A expression plasmid, indicating that the local delivery of type III IFN to target sites is 
necessary for the control of metastatic tumor growth, and that type III IFN-induced systemic 
cytotoxic T cell (CTL) response is relatively weak in this tumor model [47]. 
Despite the type III IFN-resistant phenotype, successful induction of antitumor response 
following type III IFN IL-28A gene transfer was subsequently confirmed in the MCA205 
tumor model [46]. We observed that in vivo growth of MCA205 producing IL-28A was 
efficiently inhibited by an IL-28A-elicited host-mediated immune response [46]. In this 
tumor model, the tumorigenic behavior of MCA205 cells producing either type I IFN IFN- 
or type III IFN IL-28A was compared after subcutaneous injection. IFN--secreting MCA205 
(MCA205IFN-) cells were rejected efficiently compared to IL-28A-producing MCA205 
(MCA205IL-28) cells, which exhibited only a delay of tumor growth [46]. This finding 
implicated that the potency of the antitumor activity of IL-28A might be slightly lower than 
that of IFN- although MCA205IL-28 cells secreted approximately 3-fold less cytokine than 
did MCA205IFN- cells 43. IFN- in contrast to IL-28A displayed direct biological effects 
on MCA205 cells, including enhancement of the MHC class I antigen expression, suggesting 
that IFN-, but not IL-28A, can directly influence the immunogenicity of MCA205 cells. 
In regard to the cellular antitumor mechanisms of IL-28A, the findings in mice selectively 
depleted of various immune cell populations indicated that CD8 T cells play an important 
www.intechopen.com
Type III IFNs IL-28 and IL-29: Novel Interferon  
Family Members with Therapeutic Potential in Cancer Therapy 
 
187 
role in IL-28A-mediated antitumor immunity in the MCA205 tumor model because the 
protective effect was partially abolished in CD8 T cell-depleted animals [46]. This finding is 
in clear contrast with the result obtained in the B16 melanoma tumor model, in which 
depletion of CD8 T cells had no consequence on the tumor growth rate [47]. Additionally, in 
this tumor model, local secretion of IL-28A by tumor cells induced more powerful tumor-
specific cytotoxic T cells against parental MCA205 cells [46]. This is consistent with the 
observed dense infiltration of CD8 T cells into tumor tissues from MCA205IL-28 cells. 
However, primary mouse CD8 T cells are not expressing IL-28R on the cell surface and are 
found to be unresponsive to IL-28A treatment [46]. This characteristic of type III IFNs is in 
clear contrast with that of type I IFNs, which can directly act on T cells [80]. On the contrary, 
the expression of mRNA for IL-28R is clearly detected in Con A-stimulated mouse T cells, 
suggesting that the activated mouse CD8 T cells might possess the ability to respond to type 
III IFNs [46]. However, IL-28 does not have ability to directly enhance the cytotoxic activity 
of CTLs [46]. A recent report by Jordan et al. indicated that type III IFN IL-29 influences the 
cytokine production by Con A-stimulated human T cells, which is isolated from peripheral 
blood mononuclear cells [81]. IL-28A also displayed the biological function to induce 
chemokine secretion by mouse lung fibroblasts [46]. Taken together, one possible 
mechanism, by which IL-28A elicits CD8 T cell responses, is proposed to be that IL-28A first 
stimulates CD8 T cells indirectly through induction of other cytokines and chemokines by 
surrounding cells including stromal fibroblasts and keratinocytes, and subsequently acts on 
activated T cells directly [46]. Therefore, the detailed mechanisms that underlie this CD8 T 
cell-dependent antitumor action by type III IFNs remain to be elucidated and will require 
further experimental analyses. 
A slower growth rate of MCA205IL-28 tumors in CD4 T cell-depleted mice was consistently 
observed, implicating that CD4 T cells rather inhibit IL-28A-induced antitumor response 
[46]. Both CD4 T cells and CD8 T cells have been described to be important for the efficient 
induction of antitumor cellular immunity [84, 85]. This unexpected finding that CD4 T cells 
are not required for the antitumor activity of IL-28A is not in agreement with the notion that 
CD4 T cell help is necessary for the full activation of naive CD8 T cells [86]. However, a 
similar inhibitory effect of CD4 T cells has been previously reported in IL-12- or IL-23-
transduced CT26 tumor model [87, 88]. These findings may be possibly explained by taking 
into account the CD4+CD25+ T regulatory cells [89]. With regard to the relation between 
type III IFNs and CD4+CD25+ T regulatory cells, Mennechet et al. reported that IL-28A 
promotes the generation of partially mature DCs, which display a tolerogenic phenotype 
[90]. Namely, type III IFN-matured DCs with the ability to migrate lymph nodes express 
high levels of MHC class I and II but low levels of co-stimulatory molecules [90]. These type 
III IFN-treated DCs specifically induced IL-2-dependent proliferation of a 
CD4+CD25+Foxp3+ T regulatory cell population in culture, which is thought, in general, to 
result in suppression of the antitumor immune response [89]. Therefore, type III IFN-treated 
DCs can stimulate the proliferation of pre-existing CD4+CD25+ T regulatory cells in the 
presence of IL-2 and inhibit efficient antitumor immunity. Of particular interest, these 
findings provide another important evidence that type I IFNs and type III IFNs can exert 
distinct biological effects on DC differentiation, phenotype and function.  
The finding that, in the MCA205 tumor model, IL-28A-elicited antitumor response was 
partially abrogated in NK cell-depleted mice strongly implied that NK cells play an 
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important role in the antitumor activity of IL-28A [46]. This finding is consistent with the 
result demonstrated by Sato et al. using the tumor model of B16 melanoma [47]. However, 
the surprising finding is that IL-28A is unable to directly enhance NK cell cytolytic activity 
both in vitro and in vivo [46]. This biological feature of type III IFNs on NK cells is in sharp 
contrast to type I IFNs, which markedly promote NK cell-mediated cytotoxicity in culture 
and in vivo [91]. In addition, IL-28A does not have capability to directly stimulate the growth 
of NK cells in culture [46]. On the other hand, IL-28A administration into SCID mice 
significantly expanded splenic NK cells depending on the dose of injection, and expression 
of IL-28A in the liver increased the number of hepatic NK cells [46, 47]. In the case of type I 
IFNs, exposure to type I IFNs is closely associated with NK cell blastogenesis and 
proliferation, but not IFN- expression in vivo [92]. Immunoregulatory effect of type I IFNs 
to elicit the expression of IL-15 in mouse cell populations has been proposed to contribute to 
the induction of NK cell proliferation [93]. In contrast, the detailed mechanisms for type III 
IFN-induced proliferation of NK cells in vivo remain largely unknown [46, 47]. Nonetheless, 
type III IFNs appear to augment NK cell-mediated in vivo antitumor activity via increasing 
the total number of NK cells [46]. Another possible explanation of underlying mechanisms is 
that IL-28A, like IL-21 [94], could enhance the cytolytic activity of NK cells previously 
activated by stimulators such as other cytokines and chemokines, but could not induce 
cytotoxic activity in resting NK cells. Recently, Abushahba et al. reported that DCs are 
involved in type III IFN-elicited NK cell activation [95]. DCs stimulated by type III IFNs 
secreted more amounts of bioactive IL-12, which subsequently activated NK cells [95]. Thus, 
there is a possibility that type III IFN activates NK cells indirectly via stimulation of DCs. 
Polymorphonuclear neutrophils contribute, in some way, to the suppression of tumor 
growth in the MCA205 tumor model as shown by the fact that treatment with a monoclonal 
antibody (mAb) against Gr-1 partially abrogated IL-28A-elicited tumor growth suppression 
[46]. Polymorphonuclear neutrophils can be frequently involved in the generation of CD8 T 
cell-mediated antitumor responses [96]. Notably, evidence that polymorphonuclear 
neutrophils may be important for the induction of an antitumor immunity has already been 
suggested [96], and a specific role for polymorphonuclear neutrophils in the development of 
CD8 T cell-mediated antitumor responses was also demonstrated [97]. However, little is 
known about the biological effects of type III IFNs on this cell population. Especially, the 
direct biological activity of type III IFN on polymorphonuclear neutrophils remains largely 
to be elucidated. In contrast, type III IFNs are able to positively regulate expression of 
several chemokines, which activates polymorphonuclear neutrophils. This was first 
demonstrated in the human in culture systems using peripheral mononuclear cells [82]. 
Indeed, type III IFN IL-29 induces IL-8 secretion from human peripheral mononuclear cells, 
especially macrophages, suggesting that type III IFNs at least have capabilities to stimulate 
polymorphonuclear neutrophils indirectly via induction of chemokines including IL-8 [82].  
The fact that MCA205IL-28 cells were more tumorigenic in IFN- KO mice than in syngeneic 
immunocompetent mice indicated that IFN- is involved in IL-28A-mediated antitumor 
responses [46]. Type II IFN IFN- is a pleiotropic cytokine that can act on both tumor cells 
and host immunity [98, 99]. IFN- directly inhibits proliferation of some tumor cells and 
indirectly suppresses tumor growth in vivo by activating NK cells and macrophages and 
inducing angiostatic chemokines such as MIG and IP-10 with consequent inhibition of 
tumor angiogenesis [100]. Nevertheless, abrogation of IFN- could not completely attenuate 
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the antitumor action of IL-28A, indicating that IFN--independent pathways are also 
involved in IL-28A-mediated antitumor activity [46]. In contrast, based on the finding 
obtained from the animals treated with neutralizing anti-IL-12 p40 mAb, IL-12 is not 
involved in type III IFN-mediated antitumor activity [46]. Now, little is known about the 
relation between type III IFNs and IL-12 expression. On the other hand, in contrast to the 
IFN- promotion of IL-12 expression, type I IFNs can negatively regulate IL-12 expression in 
DCs and monocytes [101, 102]. Although type III IFNs display overlapping biological 
activities with type I IFNs, type III IFNs may have ability to up-regulate IL-12 expression by 
human macrophages and mouse DCs, in contrast to type I IFNs [95, 103]. Now, further 
analyses are needed to determine the relation between type III IFNs and IL-12 expression. In 
addition, other cytokines including IL-17 and IL-23 are not required for IL-28A-induced 
antitumor activity [46]. 
IFN- is partially involved in type III IFN-mediated antitumor action, whereas a wide range 
of doses of IL-28A exert no direct effects on the release of IFN- by NK cells and CD8 T cells 
stimulated with or without anti-mouse CD3 mAb in culture [46]. In contrast, IL-28A induces 
IFN- release by primary CD4 T cells stimulated with anti-mouse CD3 mAb or co-stimulated 
with anti-mouse CD3 mAb plus anti-mouse CD28 mAb [48]. This biological effect of IL-28A 
on IFN- secretion appears to be dose-dependent [48]. In addition, this ability of IL-28A to 
induce IFN- secretion by CD4 T cells is T-bet dependent [48]. However, in contrast to IL-12, 
daily administration of IL-28A into C57BL/6 mice for 3 consecutive days could not induce 
measurable serum IFN- levels in vivo [46]. Therefore, the pathway from type III IFNs to 
IFN- expression in the mouse remains to be elucidated.  
Abushaba et al. recently reported that, using BNL hepatoma line which was resistant to IL-
28A treatment due to the lack of IL-28R expression, IL-28A secreted by tumor cells reduced 
the tumorigenicity and retarded the growth kinetics [95]. In this tumor model, NK cells were 
predominant effector cells activated indirectly by IL-28A. In addition, the enhanced 
cytotoxicity against BNL cells mediated by IL-28A was largely dependent on IL-12 
produced by DCs and subsequently produced IFN- by NK cells [95]. In fact, both myeloid 
and plasmacytoid DCs responded well to type III IFNs and secreted IL-12 [95]. Therefore, 
further analyses are needed to elucidate the precise role of IL-12 and IFN- in type III IFN-
induced antitumor immune responses. 
In human systems, with regard to the induction of IFN- secretion, a recent report by Jordan 
et al. described that type III IFN IL-29 treatment induced a modest elevation of released IFN-
 in T cells, following stimulation with Con A or in a mixed-lymphocyte reaction (MLR) [81]. 
Thus, there is a readily accessible and functional pathway from type III IFNs to IFN- 
expression in humans that does not appear to be fully operational in the mouse system. In 
the case of type I IFNs, there are positive effects on human T cell IFN- expression following 
stimulation with particular molecules including polyI:C [104]. Furthermore, Liu et al. 
demonstrated that, in humans, monocyte-derived macrophages activated by TLR responded 
to IL-29 stimulation and secreted IL-12 and TNF-, whereas monocyte and monocyte-
derived DCs did not due to the lack of surface IL-28R expression [103]. Monocyte-derived 
macrophages stimulated with IL-29 responded well to IFN- stimulation, and produced 
significantly more IL-12 through up-regulated IFN-R1 expression, whereas this activity was 
not found in IL-28A and IL-28B [103]. In clear contrast, monocyte-derived macrophages 
stimulated with IFN- down-regulated surface IFN-R1 expression [103]. 
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Combination therapy with local production of IL-28A by genetically modified tumor cells 
and systemic administration of IL-12 protein has a synergistic antitumor effect without 
apparent deleterious side effects, suggesting possible advantages in this combined therapy 
[46]. IL-28A secretion or administration of IL-12 rejected none, whereas the combination of 
two manipulations resulted in rejection of MCA205 cells in 40% of mice and dramatically 
delayed tumor growth in the remainder [46]. The presence of protective antitumor 
immunity in the surviving mice indicates that the effectiveness of this combination strategy 
extends beyond initial rejection of MCA205IL-28 cells to the development of protective long-
lasting immunity, which is specific for the initial MCA205 tumor [46]. Studies with 
lymphocyte subset ablation and using IFN- KO mice indicated that rejection of MCA205 
tumor cells brought about by the synergistic effects of IL-28A and IL-12 is mediated by 
systemic antitumor response that is dependent on the presence of both NK cells and CD8 T 
cells, but not CD4 T cells, and involves IFN- [46. As mentioned above, type III IFNs 
themselves appear to have, if any, a limited capability to stimulate IFN- secretion in mouse 
systems, whereas type III IFN significantly enhances IL-12-mediated IFN- secretion by CD4 
T cells stimulated with anti-mouse CD3 mAb in vitro, and increases serum IFN- 
concentration and the total number of spleen cells as compared with IL-12 alone in C57BL/6 
mice [46, 48]. This biological effect of type III IFN on IL-12-induced IFN- expression is 
common with type I IFN. It has been reported that there is a modest type I IFN effect on IL-
12 induction of IFN- production by mouse cells in culture [105]. Thus, the enhancement of 
the antitumor effect by combination therapy of type III IFN IL-28A and IL-12 appears to be, 
at least in part, dependent on increased IFN- production [46]. 
A surprising finding was that the enhancement of the antitumor effect of IL-28A by systemic 
treatment with IL-12 protein is found even in IFN- KO mice [46]. This finding provides 
evidence that IL-12 is able to enhance antitumor action of type III IFN through IFN--
independent pathways [46]. Of interest, there have been lots of reports describing that 
antitumor effect of systemic administration of IL-12 protein into mice is largely abrogated in 
IFN- KO mice [106]. On the contrary, in IFN- KO mice, IL-12 produced by genetically 
modified tumor cells is able to induce production of other mediators, instead of IFN-, 
including GM-CSF by both CD4 T cells and CD8 T cells and IL-15 by non-lymphoid cells, 
which are critically involved in IL-12-induced antitumor activity in IFN- KO mice in the 
C26 tumor model [107, 108]. Thus, IL-12-elicited enhancement of type III IFN-mediated 
antitumor activity may be due to an indirect effect via the mediators including GM-CSF and 
IL-15, which are induced by IL-12 in IFN- KO mice. In addition, type I IFNs have a 
biological action to up-regulate expression of the heterodimeric high-affinity receptor for IL-
12 comprised of ß1 and ß2 chains [109, 110], and to enhance the biological effects of IL-12. 
Thus, it was proposed that, like type I IFNs, type III IFNs may enhance IL-12-mediated 
biological effects on NK cells and T cells via up-regulation of IL-12 receptor expression, 
leading to augmentation of the antitumor activity.  
7. Clinical application of type III IFNs 
From in vitro and in vivo studies using human and murine tumor cells, it has become clear 
that antitumor effects of type III IFN are less effective compared with those of type I IFN. 
Therefore, the clinical usage of type III IFNs as anticancer drugs may be relatively limiting. 
However, one of the suggested benefits of potentially applying type III IFNs to the 
www.intechopen.com
Type III IFNs IL-28 and IL-29: Novel Interferon  
Family Members with Therapeutic Potential in Cancer Therapy 
 
191 
treatment of cancer is the restricted expression of its specific receptor subunit IL-28R. In this 
situation, the weaker magnitude of the activity of type III IFNs as compared with that of 
type I IFNs is anticipated to avoid causing the severe adverse side effects or to reduce the 
toxicity often observed in patients treated with type I IFNs such as fever, fatigue, 
hematological toxicity, anorexia, and depression. Actually, animal studies and clinical trials 
to treat patients with chronic hepatitis C virus (HCV) infection have displayed very few 
toxic side effects in response to Peg-IFN-1 administration at concentrations that elicit 
comparable antiviral effects as observed with Peg-IFN- treatment. Additionally, type III 
IFNs cooperate with type I IFNs to inhibit in vitro and in vivo NSCLC tumor growth 
additively via, at least in part, enhanced p21Waf1/Cip1 expression and induction of apoptosis 
[60]. Therefore, although the cooperative antitumor activity of type III IFN and type I IFN 
against various histological types of tumors has not been fully evaluated, our findings raise 
the possibility that the interferon combination therapy of type III IFN and type I IFN may 
not only surpass the therapeutic outcome of IFN- monotherapy, but also reduce the side 
effects by decreasing the daily dose of IFN-.  
8. Conclusions and perspectives 
Since the discovery of the type III IFN and IL-28R systems in 2003, this novel cytokine 
family has been demonstrated to have multiple biological actions, which have some 
similarities with those of type I IFNs. In this chapter, we have reviewed recent studies, 
describing the potential of type III IFNs in the treatment of cancer. A lot of reports 
investigating the antitumor activity of type III IFNs in in vitro and in vivo studies provided 
clear evidence that type III IFN has multiple biological activities to elicit direct and indirect 
antitumor activities. However, to date much more remains to be elucidated, not only in 
terms of mechanisms responsible for the antitumor responses observed in mouse tumor 
models but also, if any, in terms of adverse effects. The exploitation of recent findings on the 
antitumor action of type III IFNs will require more detailed information about the biological 
activities against various cell types. Especially, the biological actions of type III IFNs against 
different lymphoid subpopulations, including NK cells, T cells, macrophages and DCs, have 
to be fully clarified. In addition, only few selected points which are specifically important in 
tumor therapy with type III IFNs, taking into consideration not only type III IFN 
monotherapy but also combination therapy of type III IFN and chemotherapeutic agent or 
of type III IFN and type I IFN, which may cooperate for the generation of long-lasting 
control of tumor growth will be emphasized. Furthermore, separate attention should be 
paid to the role of endogenous type III IFN in the natural immune control of tumor growth 
using recently generated IL-28R gene knockout mice [111]. At present, the potential of type 
III IFNs in a clinical application to cancer therapy is unknown. Further studies will provide 
a better understanding of whether subtle differences in gene expression induced by type III 
IFNs relative to type I IFNs may reduce the adverse side effects and increase the efficacy 
typically seen in type I IFN cancer therapy.  
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